ECE2020 ePoster Presentations Diabetes, Obesity, Metabolism and Nutrition (142 abstracts)
Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: A systematic review and meta–analysis of randomized–controlled trials
Panagiotis Anagnostis 1 , Konstantina Vaitsi 1 , Panagiota Kleitsioti 1 , Chrysanthi Mantsiou 1 , Konstantinos Pavlogiannis 1 , Vasilios Athyros 2 , Dimitri MIkhailidis 3 & Dimitrios Goulis 1
1Aristotle University of Thessaloniki, Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynaecology, Medical School, Thessaloniki, Greece; 2Aristotle University of Thessaloniki, 2nd Propedeutic Department of Internal Medicine, Medical School, Hippocration Hospital of Thessaloniki, Thessaloniki, Greece; 3University College London (UCL), Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, , London, United Kingdom
Objective: Statins are the mainstay of treatment for patients with familial hypercholesterolaemia (FH). The purpose of this study was to systematically investigate and meta–analyze the best available evidence from randomized–controlled trials (RCTs) regarding the efficacy and safety of statins in children and adolescents with FH.
Methods: A comprehensive search was conducted in PubMed, Scopus and Cochrane, up to July 10, 2019. Data were expressed as mean differences with 95% confidence intervals (CI). The I2 index was employed for heterogeneity.
Results: Ten RCTs were included in the qualitative and nine in the quantitative analysis (1.191 patients, aged 13.3 ± 2.5 years). Compared with placebo, statins led to a mean relative reduction in total cholesterol (TC), LDL–C, triglyceride and apo–B concentrations by –25.5% (95% CI –30.4%, –20.5%; I2 91%), –33.8% (95% CI –40.1%, –27.4%; I2 90%), –8.4% (95% CI –14.8%, –2.03%; I2 26%) and –28.8% (95% CI –33.9%, –23.6%; I2 83%), respectively. HDL–C was increased by 3.1% (95% CI 1.1% – 5.2%; I2 0%). The effect on TC, LDL–C and apo–B seems to be potency–dependent. More than half of patients may achieve the LDL–C target with high–intensity statin dose (4–14% with low–to–moderate intensity). Baseline LDL–C concentrations do not seem to predict the lipid–lowering effect of statins. Statins were well–tolerated (no effect on growth or sexual development), with no significant differences in transaminase and creatine kinase levels compared with placebo.
Conclusions: Statins are quite effective in reducing TC, LDL–C, TG and apo–B and increasing HDL–C concentrations in children and adolescents with FH. No safety issues were seen with statin use.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more